In the US, over half a million patients suffer from chronic kidney failure (CKF). Most are dependent on hemodialysis to filter their blood. Unfortunately, more than 100,000 patients/year die from CKF, a large reason being the failure of the interface between the patient and the hemodialysis machine known as a “vascular access”. At Hemova, we have developed a blood access device that is safer and more reliable than current solutions; helping to keep our patients healthier and prolong their lives.
Hemova improves clinical outcomes for kidney failure patients, helping them live longer, healthier lives, spending less time in the hospital
2013 Diamond Winner